13 November 2012
A smart drug could improve survival rates in older people with acute myeloid leukemia, new research has shown.
It was found that people who took the drug, called Gemtuzumab Ozogamicin (GO), were around 22 per cent less likely to relapse, and 13 per cent less likely to die from the disease.
Research from Cardiff University found that 68 per cent of participants on the new treatment relapsed within three years.
This was compared to 76 per cent of those who went for the standard treatment, according to the results, which were published in the Journal of Clinical Oncology.
Furthermore, 25 per cent of people on the smart drug were still alive after three years, compared to 20 per cent of people who received the standard treatment.
Chief investigator Professor Alan Burnett, School of Medicine, said: "These promising results demonstrate how targeting a protein present in more than 90 per cent of AML patients can boost treatment without excessively increasing side effects."
Posted by Jeanette Royston
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.